Irbesartan in patients with atrial fibrillation
| العنوان: | Irbesartan in patients with atrial fibrillation |
|---|---|
| المؤلفون: | Mario Talajic, Keith Fox, Julián Pérez-Villacastín, Salim Yusuf, Graeme Hankey, Fabio Turazza, WILLIAM HEDDLE, Philippe Gabriel STEG, Fernando Lanas, Harald Jorstad, Vyacheslav Yurievich Mareev, Sergey Golitsyn, Theodore Wein |
| المصدر: | Yusuf, S, Healey, J S, Pogue, J, Chrolavicius, S, Flather, M, Hart, R G, Hohnloser, S H, Joyner, C D, Pfeffer, M A, Connolly, S J, ACTIVE I Investigators & Husted, S 2011, ' Irbesartan in patients with atrial fibrillation ', Briefings from the New England Journal of Medicine, vol. 364, no. 10, pp. 928-38 . https://doi.org/10.1056/NEJMoa1008816 Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | medicine.medical_specialty, Myocardial Infarction, Tetrazoles, Blood Pressure, Kaplan-Meier Estimate, Placebo, urologic and male genital diseases, Irbesartan, Recurrence, Risk Factors, Internal medicine, Atrial Fibrillation, medicine, Secondary Prevention, Humans, Myocardial infarction, Treatment Failure, Vascular Diseases, Stroke, Aged, Heart Failure, business.industry, Hazard ratio, Biphenyl Compounds, Atrial fibrillation, General Medicine, Middle Aged, medicine.disease, female genital diseases and pregnancy complications, FARMACODINÂMICA, Hospitalization, Blood pressure, Heart failure, Cardiology, business, Angiotensin II Type 1 Receptor Blockers, medicine.drug |
| الوصف: | BACKGROUND: The risk of cardiovascular events among patients with atrial fibrillation is high. We evaluated whether irbesartan, an angiotensin-receptor blocker, would reduce this risk. METHODS: We randomly assigned patients with a history of risk factors for stroke and a systolic blood pressure of at least 110 mm Hg to receive either irbesartan at a target dose of 300 mg once daily or double-blind placebo. These patients were already enrolled in one of two trials (of clopidogrel plus aspirin versus aspirin alone or versus oral anti-coagulants). The first coprimary outcome was stroke, myocardial infarction, or death from vascular causes; the second was this composite outcome plus hospitalization for heart failure. RESULTS: A total of 9016 patients were enrolled and followed for a mean of 4.1 years. The mean reduction in systolic blood pressure was 2.9 mm Hg greater in the irbesartan group than in the placebo group, and the mean reduction in diastolic blood pressure was 1.9 mm Hg greater. The first coprimary outcome occurred at a rate of 5.4% per 100 person-years in both groups (hazard ratio with irbesartan, 0.99; 95% confidence interval [CI], 0.91 to 1.08; P = 0.85). The second coprimary outcome occurred at a rate of 7.3% per 100 person-years among patients receiving irbesartan and 7.7% per 100 person-years among patients receiving placebo (hazard ratio, 0.94; 95% CI, 0.87 to 1.02; P = 0.12). The rates of first hospitalization for heart failure (a pre-specified secondary outcome) were 2.7% per 100 person-years among patients receiving irbesartan and 3.2% per 100 person-years among patients receiving placebo (hazard ratio, 0.86; 95% CI, 0.76 to 0.98). Among patients who were in sinus rhythm at baseline, there was no benefit of irbesartan in preventing hospitalization for atrial fibrillation or atrial fibrillation recorded on 12-lead electrocardiography, nor was there a benefit in a subgroup that underwent transtelephonic monitoring. More patients in the irbesartan group than in the placebo group had symptomatic hypotension (127 vs. 64) and renal dysfunction (43 vs. 24). CONCLUSIONS: Irbesartan did not reduce cardiovascular events in patients with atrial fibrillation. (Funded by Bristol-Myers Squibb and Sanofi-Aventis; ClinicalTrials.gov number, NCT00249795.) Copyright © 2011 Massachusetts Medical Society. |
| اللغة: | English |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1c667ad79ebdcf467cd696a2590f40f https://pure.au.dk/portal/da/publications/irbesartan-in-patients-with-atrial-fibrillation(7aded4eb-30ad-4835-84d9-0d404c8f6288).html |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....b1c667ad79ebdcf467cd696a2590f40f |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |